Has MVP Bottomed Out With The Change In Market Sentiment?, page-40

I guess there are two aspects to this regarding MVP. One is the return to normal activity levels by mostly vaccinated and not locked down populations getting hurt more often one way or another and thus requiring penthrox. The other is the fact that all sorts of industries and organisations have been forced to innovate and are more open to it. This hopefully means the ambulance services and emergency rooms etc are more willing to take on board penthrox and hopefully ( although just a hope) the generic drug manufacturers will jump on the continuous flow technology to help them once (and if ever) it is proven for each drug.

Management seem to be cleaning things up and getting on top of things. Also their purchases of MVP stock were substantial and inspiring of confidence. The exit of mundipharma was inconvenient in the short term but in the long term a great opportunity. It will be interesting to how long it takes for the company's sales teams to start getting traction in Europe.

Until we get meaningful sales growth or more good news on progress with the FDA for US approval it is very hard to figure out where the bottom might be. Hopefully the most recent drop into the 3s was it.